Biovest Advances Process Seeking European Marketing Approval for BiovaxID™ Personalized Lymphoma Vaccine
09:45 EDT 30 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary
of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that
the European Medicines Agency (EMA) has notified Biovest regarding the
official desi...
Other Sources for this Article
Biovest International, Inc.
Douglas Calder, 813-864-2558
Vice
President, Strategic Planning & Capital Markets
dwcalder@biovest.com
More From BioPortfolio on "Biovest Advances Process Seeking European Marketing Approval for BiovaxID™ Personalized Lymphoma Vaccine"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
